8-K: Vaxart Appoints Jeroen Grasman as Chief Financial Officer, Replacing Phillip Lee

Vaxart announces the appointment of Jeroen Grasman as its new CFO, effective May 19, 2025, succeeding Phillip Lee, who is resigning.

Summary

• Vaxart has appointed Jeroen Grasman as its new Chief Financial Officer, effective May 19, 2025.
• Phillip Lee, the current CFO, is resigning but will remain with the company as a non-executive employee through June 1, 2025, to assist with the transition.
• Mr. Lee's resignation was not due to any disagreements with the company.
• Jeroen Grasman previously served as CFO at AltruBio from August 2021 to May 2025, and has held financial leadership positions at PACT Pharma, Intarcia Therapeutics, and Genentech.
• Mr. Grasman will receive a base salary of $435,000 per year and is eligible for a target bonus of 40% of his annual base salary, pro-rated for 2025.
• He will also receive an option to purchase 1,000,000 shares of Vaxart's common stock, vesting over 48 months, and a restricted stock unit award covering 350,000 shares, vesting over four years.
• Mr. Grasman will participate in the company's Severance Benefit Plan, with a Non-CiC Severance Period of 6 months and a CiC Severance Period of 12 months.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting the appointment of an experienced CFO. The transition plan mitigates potential risks associated with the CFO departure. However, there is a slight negative due to the CFO departure.

Positives

• Vaxart has successfully recruited an experienced CFO with over 20 years in the biotech industry.
• Jeroen Grasman's background includes leadership roles in finance and operations, capital formation, and scaling companies for clinical studies.
• Phillip Lee is assisting with the transition to ensure continuity.

Negatives

• Phillip Lee's resignation as CFO creates a temporary leadership gap, although he is assisting with the transition.

Risks

• The transition period with a departing CFO could pose short-term operational challenges.
• The company's future performance will depend, in part, on the new CFO's ability to effectively manage financial operations and support strategic goals.

Future Outlook

Vaxart anticipates that Jeroen Grasman's financial expertise will be invaluable as they continue to advance their oral pill vaccine programs.

Management Comments

• Steven Lo, Chief Executive Officer of Vaxart, stated that Jeroen Grasman's expertise and track record will be invaluable as they advance their oral pill vaccine programs.
• Jeroen Grasman said he is excited to join Vaxart and looks forward to working with the team to drive the continued development of their innovative technology platform.

Industry Context

The appointment of a seasoned financial executive like Jeroen Grasman reflects Vaxart's commitment to strengthening its leadership team as it progresses its oral vaccine development programs. This is a common practice in the biotech industry as companies mature and approach later-stage clinical trials and potential commercialization.

Comparison to Industry Standards

• The compensation package for Vaxart's new CFO, including base salary, bonus potential, and equity awards, appears to be in line with industry standards for similar roles at clinical-stage biotech companies.
• For example, CFOs at comparable companies like Icosavax (before its acquisition by AstraZeneca) and Gritstone Bio typically receive base salaries in the $350,000-$500,000 range, along with significant equity grants.
• The vesting schedules for the equity awards are also standard, with 25% vesting on the first anniversary and the remainder vesting monthly or quarterly over the following three years.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively.
• Employees may experience a period of adjustment during the CFO transition.
• The company's financial stability and strategic direction could be influenced by the new CFO's decisions.

Next Steps

• Jeroen Grasman will assume his role as CFO on May 19, 2025.
• Phillip Lee will assist with the transition until June 1, 2025.
• The company will file the letter agreement with Mr. Grasman as an exhibit to its next periodic report.

Key Dates

Keywords

Chief Financial Officer, CFO, Jeroen Grasman, Phillip Lee, Vaxart, Appointment, Resignation, Biotech, Finance, Executive